Windlas Biotech Limited receives EU-GMP certificate

Windlas Biotech Limited, one of the leading domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India, has now received the certificate of European Union Good Manufacturing Practices (EU-GMP) by the National Institute of Pharmacy and Nutrition, Hungary for the Plant-IV situated at Dehradun. The company had undergone an inspection from 11th to 13th April 2022.

Commenting on this Mr. Hitesh Windlass, Managing Director - Windlas Biotech said, "We are delighted to receive the EU-GMP certificate for our Plant-IV. The company had received a GMP certificate from SAHPRA (South African Health Products Regulatory Authority) for the same plant in April 2022. These successive positive outcomes from the reputed regulatory authorities strongly reflect our core philosophy - adhering to the highest standards of quality, maintaining robust systems and strong execution capabilities. Successful completion of these audits will allow the company to expand its geographic presence in those respective markets."

Shares of Windlas Biotech Ltd was last trading in BSE at Rs. 223.30 as compared to the previous close of Rs. 224.90. The total number of shares traded during the day was 3003 in over 160 trades.

The stock hit an intraday high of Rs. 225.95 and intraday low of 221.45. The net turnover during the day was Rs. 670459.00.

Source : Equity Bulls

Keywords

WindlasBiotech EUGMP Hungary Plant4 Dehradun CDMO